MCRB Seres Therapeutics Inc

Price (delayed)

$21.83

Market cap

$2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.22

Enterprise value

$1.97B

Highlights
MCRB's debt is down by 10% year-on-year and by 2.7% since the previous quarter
The quick ratio has soared by 193% YoY but it fell by 10% QoQ
Seres Therapeutics's net income has plunged by 59% YoY and by 17% from the previous quarter
The EPS has decreased by 22% YoY and by 9% QoQ

Key stats

What are the main financial stats of MCRB
Market
Shares outstanding
91.62M
Market cap
$2B
Enterprise value
$1.97B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
13.91
Price to sales (P/S)
64.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.18
Earnings
Revenue
$30.74M
EBIT
-$101.81M
EBITDA
-$93.12M
Free cash flow
-$100.72M
Per share
EPS
-$1.22
Free cash flow per share
-$1.1
Book value per share
$1.57
Revenue per share
$0.34
TBVPS
$3.34
Balance sheet
Total assets
$305.7M
Total liabilities
$161.99M
Debt
$39.66M
Equity
$143.71M
Working capital
$204.12M
Liquidity
Debt to equity
0.28
Current ratio
5.26
Quick ratio
5.13
Net debt/EBITDA
0.29
Margins
EBITDA margin
-302.9%
Gross margin
100%
Net margin
-340.6%
Operating margin
-337.5%
Efficiency
Return on assets
-37.9%
Return on equity
-95%
Return on invested capital
-64.2%
Return on capital employed
-39.5%
Return on sales
-331.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MCRB stock price

How has the Seres Therapeutics stock price performed over time
Intraday
4.45%
1 week
6.28%
1 month
-2.93%
1 year
396.14%
YTD
-10.9%
QTD
6.02%

Financial performance

How have Seres Therapeutics's revenue and profit performed over time
Revenue
$30.74M
Gross profit
$30.74M
Operating income
-$103.76M
Net income
-$104.71M
Gross margin
100%
Net margin
-340.6%
MCRB's net margin has dropped by 83% year-on-year and by 27% since the previous quarter
The operating margin has plunged by 78% YoY and by 27% from the previous quarter
Seres Therapeutics's net income has plunged by 59% YoY and by 17% from the previous quarter
MCRB's operating income has dropped by 55% year-on-year and by 18% since the previous quarter

Growth

What is Seres Therapeutics's growth rate over time

Valuation

What is Seres Therapeutics stock price valuation
P/E
N/A
P/B
13.91
P/S
64.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.18
The EPS has decreased by 22% YoY and by 9% QoQ
The equity has decreased by 18% QoQ
The stock's price to sales (P/S) is 107% more than its 5-year quarterly average of 31.4 and 11% more than its last 4 quarters average of 58.5
MCRB's revenue is down by 13% year-on-year and by 7% since the previous quarter

Efficiency

How efficient is Seres Therapeutics business performance
The ROS has shrunk by 81% YoY and by 28% QoQ
The return on invested capital has surged by 51% year-on-year and by 15% since the previous quarter
Seres Therapeutics's ROE has increased by 37% from the previous quarter
The company's return on assets rose by 26% YoY and by 3.3% QoQ

Dividends

What is MCRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MCRB.

Financial health

How did Seres Therapeutics financials performed over time
The total assets is 89% higher than the total liabilities
The quick ratio has soared by 193% YoY but it fell by 10% QoQ
MCRB's current ratio has soared by 187% YoY but it is down by 9% QoQ
MCRB's debt is 72% smaller than its equity
Seres Therapeutics's debt to equity has surged by 139% YoY and by 22% QoQ
The equity has decreased by 18% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.